PharmaDrug Begins Clinical Trial for Infectious Disease Treatment

Pharmadrug (TSE:PHRX) has released an update.

PharmaDrug has commenced a clinical study for PD-001, a patented enteric-coated cepharanthine, aimed at treating viral infections. The study will assess bioavailability and pharmacokinetics in volunteers, with the goal to improve upon the drug’s traditionally low bioavailability. Positive results could lead to Phase 2 trials and attract potential pharmaceutical partners or investors.

For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.